Results 111 to 120 of about 4,484 (145)

Enhanced Discussion on Reassessing Lipinski's Rule of Five in the Era of AI-Driven Drug Discovery. [PDF]

Adv Pharm Bull
Purushotham U.
europepmc   +1 more source

Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection. [PDF]

Liver Int
Murayama A, Sigel KM, Tarras ES, Marshall DC.   +3 more
europepmc   +1 more source

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C. [PDF]

J Infect
O'Brien TR, Witt DJ, Saxena V, Morrissey KG, Chen S, Baker FS, Prokunina-Olsson L, Pfeiffer RM, Lai JB.   +8 more
europepmc   +1 more source

Autoimmune Hepatitis After Successful Treatment of Chronic Hepatitis C Virus Infection with Direct-Acting Antivirals: A Pediatric Case Report. [PDF]

Pathogens
Talarek E, Aniszewska M, Dobrzeniecka A, Kmiotek J, Pokorska-Śpiewak M.   +4 more
europepmc   +1 more source

Adrenal Metastasis of Hepatocellular Carcinoma With Unknown Primary: A Case Report. [PDF]

Cureus
Conger C, Yassa J, Agarwal M, Arora S, Newman N.   +4 more
europepmc   +1 more source

Micro-elimination of Hepatitis C virus (HCV) infection in the General Population Cohort in rural Uganda: long-term follow-up to assess feasibility and outcomes of a screening and treatment intervention

Mugisha J, Kimono B, Lumley S, O’Hara G, Waddilove E, Wekesa C, Mgomella G, Makanga R, Ndungutse R, Nyirenda M, Davis C, Thomson E, Ocama P, Seeley J, Matthews PC, Newton R.   +15 more
europepmc   +1 more source

Ledipasvir with sofosbuvir.

Australian prescriber, 2016
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ledipasvir/sofosbuvir

Reactions Weekly, 2018
  +14 more sources

Ledipasvir/sofosbuvir

Reactions Weekly, 2023
  +8 more sources